Terms: = Prostate cancer AND LIFR, SJS2, 3977, ENSG00000113594, SWS, STWS, CD118
13 results:
1. Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy.
Verma S; Kushwaha PP; Shankar E; Ponsky LE; Gupta S
Prostate; 2022 Oct; 82(14):1389-1399. PubMed ID: 35821621
[TBL] [Abstract] [Full Text] [Related]
2. Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.
Lee RT; Kwon N; Wu J; To C; To S; Szmulewitz R; Tchekmedyian R; Holmes HM; Olopade OI; Stadler WM; Von Roenn J
Cancer; 2021 Jun; 127(11):1827-1835. PubMed ID: 33524183
[TBL] [Abstract] [Full Text] [Related]
3. EGFR-upregulated lifr promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
Lin SR; Wen YC; Yeh HL; Jiang KC; Chen WH; Mokgautsi N; Huang J; Chen WY; Liu YN
Oncogene; 2020 Oct; 39(44):6757-6775. PubMed ID: 32963351
[TBL] [Abstract] [Full Text] [Related]
4. Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in prostate cancer by Stimulating LIF/lifr Expression.
Zhang W; Shi X; Chen R; Zhu Y; Peng S; Chang Y; Nian X; Xiao G; Fang Z; Li Y; Cao Z; Zhao L; Liu G; Sun Y; Ren S
Mol Ther; 2020 Nov; 28(11):2473-2487. PubMed ID: 32592689
[TBL] [Abstract] [Full Text] [Related]
5. In Vivo Quantification of Water Diffusion, Stiffness, and Tissue Fluidity in Benign Prostatic Hyperplasia and prostate cancer.
Asbach P; Ro SR; Aldoj N; Snellings J; Reiter R; Lenk J; Köhlitz T; Haas M; Guo J; Hamm B; Braun J; Sack I
Invest Radiol; 2020 Aug; 55(8):524-530. PubMed ID: 32496317
[TBL] [Abstract] [Full Text] [Related]
6. Phosphorylation of lifr promotes prostate cancer progression by activating the AKT pathway.
Shao J; Zhu W; Ding Y; Zhu H; Jing X; Yu H; Lu M; Qiao Y; Wang X; Ai H; Wang X
Cancer Lett; 2019 Jun; 451():110-121. PubMed ID: 30851421
[TBL] [Abstract] [Full Text] [Related]
7. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating lifr and KLF4.
Lv S; Ji L; Chen B; Liu S; Lei C; Liu X; Qi X; Wang Y; Lai-Han Leung E; Wang H; Zhang L; Yu X; Liu Z; Wei Q; Lu L
Oncogene; 2018 Mar; 37(10):1354-1368. PubMed ID: 29269867
[TBL] [Abstract] [Full Text] [Related]
8. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
[TBL] [Abstract] [Full Text] [Related]
9. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract] [Full Text] [Related]
10. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology.
Kozlowski P; Chang SD; Jones EC; Berean KW; Chen H; Goldenberg SL
J Magn Reson Imaging; 2006 Jul; 24(1):108-13. PubMed ID: 16767709
[TBL] [Abstract] [Full Text] [Related]
11. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Godoy-Tundidor S; Cavarretta IT; Fuchs D; Fiechtl M; Steiner H; Friedbichler K; Bartsch G; Hobisch A; Culig Z
Prostate; 2005 Jul; 64(2):209-16. PubMed ID: 15712220
[TBL] [Abstract] [Full Text] [Related]
12. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract] [Full Text] [Related]
13. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor.
Mori S; Murakami-Mori K; Bonavida B
Anticancer Res; 1999; 19(2A):1011-5. PubMed ID: 10368647
[TBL] [Abstract] [Full Text] [Related]
